Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Urinary levels of the tobacco-specific carcinogen N'-nitrosonornicotine and its glucuronide are strongly associated with esophageal cancer risk in smokers.

Yuan JM, Knezevich AD, Wang R, Gao YT, Hecht SS, Stepanov I.

Carcinogenesis. 2011 Sep;32(9):1366-71. doi: 10.1093/carcin/bgr125. Epub 2011 Jul 6.

2.

Tobacco-specific N-nitrosamine exposures and cancer risk in the Shanghai Cohort Study: remarkable coherence with rat tumor sites.

Stepanov I, Sebero E, Wang R, Gao YT, Hecht SS, Yuan JM.

Int J Cancer. 2014 May 15;134(10):2278-83. doi: 10.1002/ijc.28575. Epub 2013 Nov 18.

3.
4.

Determination of tobacco-specific N-nitrosamines in urine of smokers and non-smokers.

Kavvadias D, Scherer G, Cheung F, Errington G, Shepperd J, McEwan M.

Biomarkers. 2009 Dec;14(8):547-53. doi: 10.3109/13547500903242883.

PMID:
19747086
5.

Evidence for endogenous formation of N'-nitrosonornicotine in some long-term nicotine patch users.

Stepanov I, Carmella SG, Han S, Pinto A, Strasser AA, Lerman C, Hecht SS.

Nicotine Tob Res. 2009 Jan;11(1):99-105. doi: 10.1093/ntr/ntn004. Epub 2009 Jan 27.

6.

Urinary levels of tobacco-specific nitrosamine metabolites in relation to lung cancer development in two prospective cohorts of cigarette smokers.

Yuan JM, Koh WP, Murphy SE, Fan Y, Wang R, Carmella SG, Han S, Wickham K, Gao YT, Yu MC, Hecht SS.

Cancer Res. 2009 Apr 1;69(7):2990-5. doi: 10.1158/0008-5472.CAN-08-4330. Epub 2009 Mar 24.

7.

Urinary levels of cigarette smoke constituent metabolites are prospectively associated with lung cancer development in smokers.

Yuan JM, Gao YT, Murphy SE, Carmella SG, Wang R, Zhong Y, Moy KA, Davis AB, Tao L, Chen M, Han S, Nelson HH, Yu MC, Hecht SS.

Cancer Res. 2011 Nov 1;71(21):6749-57. doi: 10.1158/0008-5472.CAN-11-0209. Epub 2011 Oct 25.

8.

Analysis of human urine for pyridine-N-oxide metabolites of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific lung carcinogen.

Carmella SG, Borukhova A, Akerkar SA, Hecht SS.

Cancer Epidemiol Biomarkers Prev. 1997 Feb;6(2):113-20.

9.

Exposure and Metabolic Activation Biomarkers of Carcinogenic Tobacco-Specific Nitrosamines.

Hecht SS, Stepanov I, Carmella SG.

Acc Chem Res. 2016 Jan 19;49(1):106-14. doi: 10.1021/acs.accounts.5b00472. Epub 2015 Dec 17.

PMID:
26678241
10.

Differences in the urinary metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in black and white smokers.

Richie JP Jr, Carmella SG, Muscat JE, Scott DG, Akerkar SA, Hecht SS.

Cancer Epidemiol Biomarkers Prev. 1997 Oct;6(10):783-90.

11.
12.

Exposure to the carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers from 3 populations with different risks of lung cancer.

Derby KS, Cuthrell K, Caberto C, Carmella S, Murphy SE, Hecht SS, Le Marchand L.

Int J Cancer. 2009 Nov 15;125(10):2418-24. doi: 10.1002/ijc.24585.

13.

Tobacco smoke biomarkers and cancer risk among male smokers in the Shanghai cohort study.

Hecht SS, Murphy SE, Stepanov I, Nelson HH, Yuan JM.

Cancer Lett. 2013 Jun 28;334(1):34-8. doi: 10.1016/j.canlet.2012.07.016. Epub 2012 Jul 20.

14.

Correlation between the urine profile of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone metabolites and N7-methylguanine in urothelial carcinoma patients.

Lee HL, Hsueh YM, Chung CJ, Pu YS, Chang LW, Hsieh DP, Liou SH, Lin P.

Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3390-5. doi: 10.1158/1055-9965.EPI-08-0761. Erratum in: Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):361.

15.

Racial differences in exposure and glucuronidation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK).

Muscat JE, Djordjevic MV, Colosimo S, Stellman SD, Richie JP Jr.

Cancer. 2005 Apr 1;103(7):1420-6.

16.

Development of a method for the determination of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in urine of nonsmokers and smokers using liquid chromatography/tandem mass spectrometry.

Hou H, Zhang X, Tian Y, Tang G, Liu Y, Hu Q.

J Pharm Biomed Anal. 2012 Apr 7;63:17-22. doi: 10.1016/j.jpba.2012.01.028. Epub 2012 Jan 30.

PMID:
22366322
17.

Effects of reduced cigarette smoking on the uptake of a tobacco-specific lung carcinogen.

Hecht SS, Murphy SE, Carmella SG, Zimmerman CL, Losey L, Kramarczuk I, Roe MR, Puumala SS, Li YS, Le C, Jensen J, Hatsukami DK.

J Natl Cancer Inst. 2004 Jan 21;96(2):107-15.

18.

Identification of tobacco-derived compounds in human pancreatic juice.

Prokopczyk B, Hoffmann D, Bologna M, Cunningham AJ, Trushin N, Akerkar S, Boyiri T, Amin S, Desai D, Colosimo S, Pittman B, Leder G, Ramadani M, Henne-Bruns D, Beger HG, El-Bayoumy K.

Chem Res Toxicol. 2002 May;15(5):677-85.

PMID:
12018989
19.
20.

Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation.

Hecht SS, Carmella SG, Chen M, Dor Koch JF, Miller AT, Murphy SE, Jensen JA, Zimmerman CL, Hatsukami DK.

Cancer Res. 1999 Feb 1;59(3):590-6.

Items per page

Supplemental Content

Write to the Help Desk